Loading clinical trials...
Loading clinical trials...
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose,...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Roxane Laboratories
NCT05132439 · Intermittent Claudication
NCT06410521 · Peripheral Arterial Disease, Intermittent Claudication
NCT05457738 · Intermittent Claudication
NCT02924857 · Peripheral Artery Disease (PAD), Ischemia, and more
NCT05232474 · Intermittent Claudication, Peripheral Arterial Disease
CEDRA Clinical Research, LLC
Austin, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions